KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities (2017 - 2025)

Moderna (MRNA) has disclosed Total Current Liabilities for 9 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 9.93% to $2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, down 9.93% year-over-year, with the annual reading at $2.0 billion for FY2025, 9.93% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $2.0 billion at Moderna, up from $1.7 billion in the prior quarter.
  • The five-year high for Total Current Liabilities was $10.0 billion in Q3 2021, with the low at $1.6 billion in Q2 2025.
  • Average Total Current Liabilities over 5 years is $4.7 billion, with a median of $3.3 billion recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 6172.01% in 2021, then crashed 62.12% in 2023.
  • Over 5 years, Total Current Liabilities stood at $9.1 billion in 2021, then crashed by 46.07% to $4.9 billion in 2022, then crashed by 38.76% to $3.0 billion in 2023, then decreased by 26.83% to $2.2 billion in 2024, then decreased by 9.93% to $2.0 billion in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.0 billion, $1.7 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.